• Directed pre-deal and post-deal analysis of new and enhanced payer contracts, optimizing contract terms to secure access on more than 10 key health plans, achieving improved formulary positioning compared to legacy contracts• Oversee the forecasting processes for two ophthalmic drugs generating approximately $30 million in annual sales, while managing brand strategy and directly influencing access and gross-to-net (GTN), expanding patient reach by adding over 4 million lives and introducing new retail options to enhance patient affordability• Created and implemented patient access programs; integrated a cash pay option at retail pharmacies, refined our copay card program including changing vendors and adjusting patients' out-of-pocket cost (OOP), overhauled patient hub/mail pharmacy program that shortened patients' turnaround time and kept patients on the product for longer• Developed a targeted HCP pull-through plan based on territory alignment and regional access strength. Plan enabled field teams to identify must-win offices and tailor their pull-through messaging based on patients' use of competitor products• Enhanced GTN forecasting for a newly launched product (IYUZEH), enabling the team to make bettercontracting decisions

•Provided analytical support for the commercial product Gemtesa in the Urology space, which grew from $30 million to $60 million in top-line sales within a year• Collaborated closely with national & regional account teams to develop targeted pull-through strategies, optimizing contract wins by creating updated target lists to focus sales team on high-impact HCPs, resulting in a 25% increase in national market share and driving significant sales growth• Evaluated patient access initiatives and identified patient segments where the product generated negative margins; guided the team in modifying the program using specific value thresholds, which enhanced gross-to-net margins• Collaborated with the marketing team to produce materials that improved perceptions of coverage, effectively persuading Pharmacy Benefit Managers (PBMs) to enhance formulary access to capture growing demand revenue dollars• Created a tailored KPI metrics dashboard utilizing critical data sources (LAAD, Rx), enabling field teams to evaluate contract performance and identify potential pull-through opportunities

• Provided analytical support for three commercial stage assets and several clinical stage assets, collectively generating over $2.5 billion in sales within the gastrointestinal space•Developed analytics and materials that facilitated payer interactions, resulting in reduced rebate rates for coverage and fewer restrictions on a rare disease drug, thereby enhancing patient persistency and new fills•Led a process for a non-contracted rare disease product to identify burdensome utilization management requirements causing decreased new patient utilization and retention. Leveraged diverse data sets to pinpoint policy language impacting patient starts and persistency, and collaborated with field and contract teams to eliminate obstacles, improving access and retention•As part of pre-launch team for a new clinical stage asset, I conducted market research with healthcare providers (HCPs) and payers to determine an optimal launch price that balanced broad formulary adoption and rebates with manageable patient OOP costs•Created Value-Based Contracts (VBC) in partnership with cross-functional teams, integrating economic terms such as clinical outcomes and laboratory results to align with payer expectations in order to increase potential for favorable coverage

• Part of a team that executed a $500M take private acquisition, $100M acquisition of clinical-stage company to bring Vioxx back to market, co investment & licensing deal with Nestle, and a $168M Series D for a portfolio company• Performed due diligence on opportunities and drafted comprehensive investment cases with accompanying financial models that GP's and LP's could utilize to inform capital allocation decisions• Partnered with startups to source value accretive bolt-on and strategic licensing deals that enhanced overall value of the portfolio and allowed for higher NAV valuations as well as exit multiples•Worked with VP of Sales to develop sales force sizing and implementation plans, led to deciling of topprescribing specialists in the country with ability for multiple monthly visits to assist in pull-through,allowing for phasing of launch based on market uptake•Managed financial analysis of portfolio companies, including maintaining cap tables pre and postrounds, handling capital calls, and monitoring cash flow

• Developed access & pricing strategy for Intrarosa launch; determined payers to contract with, formulary placement for optimal uptake, and cost/benefit of rebating in key accounts• Performed post-deal analysis of access programs and was able to find and fix irregularities with copay assistance program causing gross to net (GTN) pressure on net sales• Managed GPO contracts including analysis of discounts and forecasts; partnered with brand leaders to generate scenarios during bid time to maximize revenue while minimizing financial risk• Handled top-line month-end closing entries & account reconciliations along with forecasting for a portfolio of commercial products across multiple indications• Developed and presented projections and reports to senior leadership regularly during pre-launch planning and commercialization for newly in-licensed product• Designed custom excel model to incorporate and track top-line P&L results into central location that allowed for more accurate forecasting as well as easier report generation and performance tracking

• Responsible for gross to net forecasting with specific responsibility for tracking rebates across channels and providing guidance to CFO for top-line talking-points in quarterly earnings calls• Built model to identify rebate "leakage" in government channels that allowed team to make better contracting decisions with Medicaid purchasing pools requesting lower net unit pricing (GNUP)• Managed gross to net modeling including tracking and managing rebates vs. actuals; forecasted for Commercial, Part D, and Medicaid as well as 340b and FSS/Big4 that produced chargebacks• Handled month-end closings and account reconciliations for commercial teams and assisted with maintaining expenses in-line with budget figures• Partnered with commercial teams to identify and measure ROI of new initiatives in order to facilitate decisions towards programs with highest probability of driving brand growth• Led gross to net (GTN) forecasting with specific responsibility for tracking rebates across channels and providing guidance to CFO for top-line talking-points in quarterly earnings calls

• Lead long-range planning for commercial teams and developed sales and operating expense forecasts extending out 2-10 years in order to facilitate corporate level decision making• Developed and presented financial results for initiatives including overall spend vs. budget and ROI of new programs while providing insights into areas of opportunities for cost savings• Designed and managed field force incentive compensation (IC) including helping to set goals, monitoring performance, and reporting outcome to senior leaders for further dissemination• Performed variance analysis using insights from commercial partners to add commentary for budget deviations including likelihood of hitting quarterly targets• Performed post-deal analysis of payer contract performance to assess overall profitability of existing rebate strategy for both pharmacy and medical benefit products• Developed payer & channel level forecasts across Medicare, Medicaid, Commercial, DoD & VA, along with tracking utilization among 340b and internal copay program• Maintained sales performance dashboard, responsible for updating and monitoring daily sales acrossmultiple systems and reporting each morning to leadership• Developed budgets and forecasts for sales (+ volume) and expenses, translated forecast and actualsinto guide to assist manufacturing plan